Company profile for Orca Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Established in 2016, Orca Bio is a clinical-stage biotechnology company developing a pipeline of high-precision allogeneic cell therapy products. Our products are designed to safely and effectively replace a patient’s diseased blood and immune system with a healthy one. The company’s proprietary therapeutic and manufacturing platforms are exclusively licensed from Stanford University. Our therapeutic platform delivers high...
Established in 2016, Orca Bio is a clinical-stage biotechnology company developing a pipeline of high-precision allogeneic cell therapy products. Our products are designed to safely and effectively replace a patient’s diseased blood and immune system with a healthy one. The company’s proprietary therapeutic and manufacturing platforms are exclusively licensed from Stanford University. Our therapeutic platform delivers high-precision allogeneic cell therapies by building each dose cell-by-cell from another person’s blood. Each therapy is constructed by formulating a proprietary mixture of cells uniquely suited for the patient.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
3475 Edison Way, Suite C, Menlo Park, CA 94025
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmiweb.com/press-release/2026-01-09/orca-bio-announces-250m-in-aggregate-financing-in-preparation-for-potential-commercialization

PHARMIWEB
09 Jan 2026

https://www.businesswire.com/news/home/20260105135739/en/Orca-Bio-to-Present-at-the-44th-Annual-J.P.-Morgan-Healthcare-Conference

BUSINESSWIRE
05 Jan 2026

https://www.businesswire.com/news/home/20251215048576/en/Orca-Bio-Announces-Orca-T-Phase-3-Data-Published-in-Blood-Demonstrate-Significant-Improvement-in-Survival-Free-from-Chronic-Graft-versus-Host-Disease-in-Patients-with-Hematological-Malignancies

BUSINESSWIRE
15 Dec 2025

https://www.pharmiweb.com/press-release/2025-12-06/orca-bio-presents-new-clinical-data-on-orca-t-in-older-patients-using-reduced-intensity-conditionin

PHARMIWEB
06 Dec 2025

https://www.businesswire.com/news/home/20251103917344/en/Orca-Bio-to-Present-New-Clinical-Data-on-Its-High-Precision-Cell-Therapies-at-the-67th-American-Society-of-Hematology-Annual-Meeting

BUSINESSWIRE
03 Nov 2025

https://www.pharmiweb.com/press-release/2025-10-06/orca-bio-announces-fda-acceptance-and-priority-review-of-the-biologics-license-application-bla-for

PHARMAWEB
06 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty